Quiz: Monoclonal Antibody Treatment for Canine Osteoarthritis

Sponsored by Zoetis

Osteoarthritis (OA) is a common chronic health condition among dogs, with 1 study finding nearly 40% of dogs >1 year of age being affected¹; it is also a leading cause of canine euthanasia.² Although NSAIDs have historically been the standard therapy for the control of OA pain, they are not always well suited for every pet. A new class of drugs has been added to the options available for patients suffering from OA pain: monoclonal antibodies (mAbs). Test your knowledge of mAb therapy for the control of pain associated with OA in dogs with the following quiz.

IMPORTANT SAFETY INFORMATION

For use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. LIBRELA should not be used in breeding, pregnant or lactating dogs. LIBRELA should not be administered to dogs with known hypersensitivity to bedinvetmab. The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis. See Full Prescribing Information at LibrelaPI.com.

All trademarks are the property of their respective owners. All rights reserved. TI-11329.